RxSight is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. Co.'s proprietary RxSight Light Adjustable Lens system, comprised of RxSight Light Adjustable Lens (LAL), RxSight Light Delivery Device (LDD) and accessories, is the first commercially available intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. Co.'s LAL is made of proprietary photosensitive material that changes shape in response to specific patterns of ultraviolet light generated by Co.'s LDD. The RXST average annual return since 2021 is shown above.
The Average Annual Return on the RXST average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether RXST average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the RXST average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|